Retinal sensitivity potentially useful in evaluating anti-VEGF treatment of wet AMD

Measuring retinal sensitivity in patients treated with intravitreal ranibizumab for neovascular age-related macular degeneration may assist with evaluating the treatment’s effectiveness, according to a study.The prospective, interventional case series included 42 eyes of 39 patients with neovascular AMD. All eyes were treated with 0.5 mg intravitreal Lucentis (ranibizumab, Genentech) once a month for 3 months. Treatment continued as needed.

Full Story →